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Abstract
Background: The glycolytic nature of malignant tumors contributes to high levels of extracellular acidity in the
tumor microenvironment. Tumor acidity is a driving force in invasion and metastases. Recently, it has been shown
that buffering of extracellular acidity through systemic administration of oral bicarbonate can inhibit the spread of
metastases in a mouse model for metastatic breast cancer. While these findings are compelling, recent assessments
into the use of oral bicarbonate as a cancer intervention reveal limitations.
Methods: We posited that safety and efficacy of bicarbonate could be enhanced by dichloroacetate (DCA), a drug
that selectively targets tumor cells and reduces extracellular acidity through inhibition of glycolysis. Using our
mouse model for metastatic breast cancer (MDA-MB-231), we designed an interventional survival study where
tumor bearing mice received bicarbonate, DCA, or DCA-bicarbonate (DB) therapies chronically.
Results: Dichloroacetate alone or in combination with bicarbonate did not increase systemic alkalosis in mice.
Survival was longest in mice administered bicarbonate-based therapies. Primary tumor re-occurrence after surgeries
is associated with survival rates. Although DB therapy did not significantly enhance oral bicarbonate, we did
observe reduced pulmonary lesion diameters in this cohort. The DCA monotherapy was not effective in reducing
tumor size or metastases or improving survival time. We provide in vitro evidence to suggest this outcome may be
a function of hypoxia in the tumor microenvironment.
Conclusions: DB combination therapy did not appear to enhance the effect of chronic oral bicarbonate. The anti-
tumor effect of DCA may be dependent on the cancer model. Our studies suggest DCA efficacy is unpredictable
as a cancer therapy and further studies are necessary to determine the role of this agent in the tumor
microenvironment.
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Background
The extracellular pH of malignant tumors is acidic (pH
6.5-6.9) compared to normal tissue (pH 7.2-7.4) [1-3].
Tumor acidity is thought to play a critical role in che-
moresistance [4-6] and promotion of metastatic poten-
tial. For example, acidic culture conditions increase
filopodia formations and expression of proteolytic
enzymes involved in invasion [7]. Other reports have
described enhanced invasiveness [8] and increased cathe-
psin B activity in acid-cultured tumor cells [9]. Acid-
mediated metastatic potential has been demonstrated in
vivo as well. Tumor cells pre-treated under acidic pH
prior to tail vein injection formed a greater number of
pulmonary metastases as well upregulated activity of
metastatic effectors such as serine proteases and angio-
genic factors [10].
Although decreased extracellular tumor pH is strongly
associated with numerous cellular mechanisms including
carbonic anhydrases [11], vacuolar ATPases [12], and
sodium-ion exchangers [13], gl y c o l y s i si sc o n s i d e r e dt h e
major factor in promoting tumor acidity. Excessive tumor
glycolysis, even in the presence of oxygen, is a hallmark of
malignancy and leads to increased production of lactic
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driving tumor cell invasion inspires the corollary predic-
tion that neutralizing acidic tumor pH inhibits invasion
and slows the spread of metastases. This question was
tested in a survival study of tumor bearing mice. Female
severe combined immunodeficient (SCID) mice with
MDA-MB-231 breast tumor xenografts were chronically
administered drinking water with sodium bicarbonate.
This study reported that systemic bicarbonate buffered the
extracellular pH in tumors to neutral levels (a pH of 7.2)
and inhibited the spread of metastases which led to
improved survival. Systemic bicarbonate was also effective
against the spread of metastases in a model for prostate
cancer [16].
Certain determinations are required before considering
systemic buffering of tumor acidity as feasible approach
to cancer treatment. Effective doses, susceptible tumor
types, ideal buffers, safety approaches, and other factors
in the tumor microenvironment would need to be identi-
fied and validated. To assist our understanding of these
phenomena, mathematical models were developed to
predict the safety and efficacy of systemic buffering of
tumor acidity in humans. Our findings suggest that
chronic use of oral bicarbonate as a cancer intervention
is limited. Safe doses for consumption limit the amount
of buffering to counteract tumor cell production of extra-
cellular protons. In a previous study, it was reported that
the saturating dose of oral bicarbonate in mice (which
roughly translates to about 0.18 g/kg/day in humans) was
only sufficient to counteract the acid load of a 15 mg
tumor consisting of about 100,000 cells or 1.0 mm
3 [16].
Moreover, chronic application of oral bicarbonate at
doses higher than 0.5 g/kg/day is predicted to induce sys-
temic alkalosis (Martin N, Robey I, Gaffney E, Gillies R,
Gatenby R, Maini P: Predicting the Safety and Efficacy of
Buffer Therapy to Raise Tumor pHe: An Integrative
Modeling Study, submitted). Therefore, it is thought that
safety and efficacy of oral bicarbonate could be enhanced
by other reagents that directly or indirectly target the
processes driving extracellular tumor acidity.
One possible method to enhance extracellular pH buf-
fering is the orphan drug dichloroacetate (DCA). This ana-
logue of acetic acid has been shown to selectively target
tumor cell metabolism by indirectly activating pyruvate
dehydrogenase (PDH) through inhibition of pyruvate
dehydrogenase kinase (PDK) activity. Upregulated PDH
activity shifts metabolism of pyruvate to lactate under the
glycolytic cascade towards production of acetyl-CoA,
which is fed into the Krebs Cycle to drive oxidative phos-
phorylation. This shift results in decreased cellular glycoly-
sis with a subsequent increase in extracellular pH. It also
triggers multiple apoptotic signaling events in the mito-
chondria [17,18]. To explore the question of whether
DCA and bicarbonate is a viable therapeutic intervention
in metastatic disease we conducted an interventional sur-
vival study in mice bearing MDA-MB-231 metastatic
breast tumor xenografts divided into four treatment
groups 1) untreated; 2) bicarbonate; 3) DCA and 4) DCA-
bicarbonate (DB).
Methods
Animal experiments
All animals were maintained under Institutional Animal
Care and Use Committee (IACUC) - approved protocols
at the University of Arizona. Six to eight-week-old female
SCID mice received orthotopic injections of 5 × 10
6
MDA-MB-231/eGFP tumor cells in a mammary fatpad.
Tumor bearing animals were randomized into 1)
untreated; 2) sodium bicarbonate (Sigma, St. Louis, MO),
200 mM (equivalent to 3.2 g/kg/day in mice); 3) sodium
dichloroacetate (DCA) (Sigma, St. Louis, MO), 5 mM
(equivalent to 112 mg/kg/day); and 4) sodium bicarbonate
(200 mM) plus sodium dichloroacetate (5 mM) combina-
tion (DB) water six days following tumor inoculation.
Starting cohort sizes were 16 per group. Animals were
monitored and maintained by the Experimental Mouse
Shared Services (EMSS) core facility of the Arizona Cancer
Center, Tucson Arizona. Volumes of primary tumors in
mammary fat pads were measured twice weekly and calcu-
lated from orthogonal measurements of external dimen-
s i o n sa s( w i d t h )
2 × (length)/2. Surgical resections of
primary tumors occurred between days 28-50 when
tumors were approximately 500 mm
3. Mice were eutha-
nized when tumor burden was excessive (primary, intra-
peritoneal, or lymph node > 2000 mm
3)o rw h e nm i c e
progressed to a moribund state. The EMSS technician,
who was blind to the study, monitored the mice twice
weekly. Notification to euthanize was received by the
investigator on the day of a monitoring visit and study ter-
mination endpoints did not exceed 48 hours. Animals
were euthanized by cervical dislocation.
Urine was obtained by applying gentle abdominal pres-
sure against the mouse for 10 sec over plastic film. Urine
was collected by micropipette and transferred to a
0.6 mL tube for pH measurement. Serum was collected
by heart puncture after mice were euthanized. Blood was
centrifuged and serum was collect for pH measurement.
Urine and serum pH was measured using a Mettler
Toledo pH meter with an InLab
® Micro probe.
Metastases measurements
Upon termination of the survival experiment, gross
necropsy was used to identify tumor metastases. Green
fluorescent tumors were detected by the Illumatool
Bright Light System (LT-9500) using a 470 nm/40 nm
excitation filter (Lightools Research) and imaged using a
mounted PowerShot SD750 digital camera (Canon, Lake
Success, NY). The images were captured at the same
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> 490-nm filtered emission. Whole lung image data were
analyzed with Adobe Photoshop 5.0 using the “magic
wand” tool to select lung area and green fluorescent
tumor lesions. Pixel area of the selected images was mea-
sured using ImageJ (http://rsb.info.nih.gov/ij/).
Cell culture experiments
MDA-MB-231 cells were obtained from the American
Type Culture Collection (Rockville, MD) and maintained
in Dulbecco’s Modified Eagle’s Medium/F-12 supplemen-
ted with 10% FBS. Crystal violet assay:C e l l s ,g r o w i n gi n
log phase, were plated in 96-well culture plates at a density
of 5 × 10
4 cells/mL. The following day cells were exposed
to titrating doses of DCA suspended in fresh growth
media from 80 mM to 2.5 mM at 20% (normoxia) or 1%
O2 (hypoxia). Untreated cells in growth media were
included as negative controls. After the 24 hour dose per-
iod, cells were fixed with 0.025% gluteraldehyde then
stained with 0.1% crystal violet. Stained cells were washed
with water then resuspended in 10% acetic acid. Absor-
bance was measured at 590 nm using a Victor3™ plate
reader (PerkinElmer, Waltham, MA). Lactate production
measurements: Cells growing in 24-well plates were
washed once with phosphate buffered saline then cultured
with 100 μL in 10 mM D-(+)-glucose-supplemented,
serum-free RPMI for 1 hour incubation at 37°C in a humi-
dified 5% CO2 atmosphere, 20% or 1% O2. Lactate levels
were quantified using an enzymatically coupled lactic acid
detection reagent (Sigma). Ten microliters of lactate
supernatant were assayed with 90 μL lactate reagent in
96-well plates. Mixtures were incubated for 5 minutes in
the dark at ambient temperature. Absorbance of colori-
metric assay was measured at 450 nm. Lactate production
rates were calculated from an internal standard curve and
expressed as nmol/min/mg protein. Cellular protein was
obtained by lysing cells with 100 μL0 . 1NN a O Hf o r
1 minute then neutralizing lysate with an equal volume of
0.1 N HCl. The protein concentration was determined
using and internal bovine serum albumin standard curve
in a Bradford Assay (Pierce, Rockford, IL). Absorbance of
colorimetric assay was measured at 630 nm.
Statistics
Statistical calculations were determined using the analysis
feature in GraphPad Prism version 4.03 for Windows
(GraphPad Software, San Diego CA, http://www.graphpad.
com). Unpaired, two-tailed t-tests were used to determine
if means were significantly different between untreated
and treated groups. Categorical analyses were carried out
using a two-tailed Fischer’s Exact test. A p-value of less
than 0.05 was considered to be statistically significant.
Numerical data values are represented as mean ± SEM.
Results
Chronic oral administration of DB has no adverse
systemic effects
Our previous studies have found that chronic oral bicar-
bonate significantly increases urine pH in tumor bearing
mice by approximately 1.4 fold over a 21 day period.
This is a consequence of excess systemic bicarbonate
and raises concerns about the safety of long term use in
humans (Martin N, Robey I, Gaffney E, Gillies R, Gate-
nby R, Maini P: Predicting the Safety and Efficacy of
Buffer Therapy to Raise Tumor pHe: An Integrative
Modeling Study, submitted). Urine pH in DCA treated
mice was the same as measured in untreated mice.
Urine pH was similar between bicarbonate and DB trea-
ted mice (Figure 1A). In the post-survival study there
were no statistically significant changes in serum pH
between any of the groups. A marginal, but significant
serum pH difference (p < 0.03) was observed between
DB and DCA treated mouse serum (Figure 1B).
Primary tumor growth was unaffected by treatments
Previous studies have shown that oral administration of
DCA can slow the rate of tumor growth in vivo [17]. In
our study, treating MDA-MB-231 tumor bearing mice
with DCA and DB did not impact primary tumor
growth. Tumors in all cohorts grew at an equal rate
before they were resected (Figure 2A). The primary
tumor growth rates in the bicarbonate and DB treated
groups were consistent with earlier findings in bicarbo-
nate treated mice. The results confirm that bicarbonate
buffering of tumor acidity does not function to inhibit
primary tumor growth [16]. In animals where primary
tumors re-occurred, growth rates were not statistically
different between groups (Figure 2B). After resection,
most primary tumors grew back in the untreated and
DCA treated mice. In bicarbonate and DB treated mice,
less than half of the tumors grew back after tumor
r e s e c t i o n( T a b l e1 ) .P r i m a r yt u m o rr e o c c u r r e n c ew a s
not statistically significant when comparing individual
treated cohorts to the untreated group (Figure 3A), but
non-bicarbonate treated cohorts (untreated and DCA)
had a significantly higher rate of tumor reoccurrence
after survival surgery than bicarbonate treated cohorts
(bicarbonate and DB) (p < 0.05) (Figure 3B)
Oral administration of bicarbonate and DCA-bicarbonate
improves survival over DCA and untreated mice
Because our study design chronically administered DCA
over a 17 week period, we limited the drinking water
concentration to 5 mM (0.75 g/L) to avoid potential
development of hepatic carcinogenesis [19]. Treatments
were started 6 days after tumor injections and were con-
tinued for the remainder of the study. Mice received
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490 mm
3 (± 95). On average, these surgeries occurred on
day 37 (± 8). Mice that died from surgical procedures
were omitted from the study. The mice were maintained
on cohort-specific treatment regimens until conditions
related to tumor burden required animals to be eutha-
nized. Mice were then analyzed to score and measure
tumor metastases. Spontaneous deaths occurred in all
groups. Complete postmortem analysis could not be
obtained in some of these deaths. These include one in
the untreated group, two in the bicarbonate group, two
in the DCA group, and one in the DB group. The survival
study was terminated at day 120, at which point those
mice surviving beyond that time were euthanized for
post study analysis. Mice treated with bicarbonate (p =
0.03) and DB (p = 0.01) had significantly improved survi-
val over untreated and DCA-treated (p =0 . 2 )m i c e
(Figure 4). Three of 15 untreated mice survived after day
120. In the bicarbonate treated group, 8 of 13 mice
remained after day 120. Six of 15 mice remained after
day 120 in the DCA treated group. In the DB treated
group, 10 of 15 mice remained after day 120. The mean
survival day was 100, 110, 104, and 112 for untreated,
bicarbonate, DCA, and DB treated mice, respectively.
Analysis of metastases
Metastatic involvement was observed in the intestines,
mesentery, lymph nodes, and lungs in all groups (Table 1).
All treated mice sustained a lower or equal amount of
intestinal, mesentery, and lymph node metastases com-
pared to the untreated group, but no differences were sta-
tistically significant. Metastases were present in mice
where primary tumors re-occurred after tumor resection
and in mice where primary tumors did not re-occur.
Figure 1 Comparison of urine and serum pH in treatment groups. A) Urine samples were collected from tumor bearing mice at eight
different time points over a 3 week period from 3-10 mice in each treatment group. At time zero before starting treatment, urine pH in all
groups averaged 5.59 ± 0.2 with no statistical difference between groups. The first collection time after starting treatment was at 24 hours. Urine
pH measurements from all collection times were averaged. Asterisks (*) designate average urine pH values that were statistically significant from
untreated mouse group by student’s two-tailed t-test (p < 0.001). The cross (†) designates average urine pH values between the DCA and DB
treated groups were statistically significant (p < 0.03). B) Serum pH was measured in euthanized mice. Differences in serum pH between groups
were not statistically significant. Error bars are expressed as SEM.
Figure 2 Effect of bicarbonate, DCA and DB treatments on primary tumor growth. Growth rates of primary tumors are expressed in mm
3/
time (days). Plots indicate none of the treatments exhibited a measurable effect on primary tumor growth at the beginning of the study (A) or
from the time of the tumor resections to study termination (B). Error bars are expressed as SEM. Two-tailed, unpaired t-test, between these
groups yielded a p > 0.9.
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re-occurrence and development of metastases (p = 0.028).
There was no statistical significance between metastases
and mice that did not have re-growth of primary tumors.
There was no positive correlation between >120 day survi-
val and the presence of metastases (Table 2).
Most (11 of 14) untreated mice developed pulmonary
metastases. Lung metastases were found in 1 of the 11
bicarbonate treated animals. Pulmonary metastases were
counted in 6 of 13 DCA treated animals, and 9 out of
15 DB treated mice (Table 1). Average pulmonary lesion
sizes in DB treated mice were significantly smaller than
lesions from the other groups (p < 0.001). The sum area
of the pulmonary lesions in DB treated animals was less
than half the sum of the lesions in the other groups
(Table 3). Representative lung images from each treat-
ment group are presented in Figure 5. The average
lesion area in the single bicarbonate treated mouse lung
was significantly larger than lesions measured in the
untreated mouse lungs (p < 0.023) (Table 3). Lung
lesion sizes did not correspond with time of death.
Cytotoxic and lactate production assays suggest loss of
anti-cancer efficacy of DCA in hypoxic tumors
DCA monotherapy in MDA-MB-231 tumor bearing
mice produced no measurable effects against the tumors
or metastases. Although previous studies testing lower
doses of DCA on tumor growth in vivo were effective
using other cell lines [17], the tumors in this study were
comparatively unresponsive. The effect of titrating doses
of DCA under normoxic conditions (O2 =2 0 % )in vitro
showed that low doses in culture from 2.5 to 20 mM
appeared to stimulate cellular viability as demonstrated
by a significant 30% increase in viable numbers of cells
at these doses after 24 hours. MDA-MB-231 cells exhib-
ited a 25% decrease in viability at 40 mM and an 80%
decrease at 80 mM. Viability was 50% at 58 ±5 mM
under normoxic conditions (Figure 6A). Similar results
were seen after 48 hour incubations with DCA (data not
shown).
Microenvironmental conditions such as hypoxia (O2 =
1%) can influence drug efficacy against tumor cells. This
condition was tested evaluating the cytotoxic effect of
DCA on cultured MDA-MB-231 tumor cells. Under
hypoxic conditions, DCA doses between 2.5-20 mM had
no effect on MDA-MB-231 cell viability. Similar to MDA-
MB-231 cells grown under normoxia, a 40 mM DCA con-
centration significantly reduced viability by 25-30%, but
cells were more resistant to increasing concentrations
under hypoxic conditions. A DCA dosage of 84 ± 8 mM
was required to reduce cell viability to 50% under hypoxia
(Figure 6B).
We tested DCA in its ability to inhibit glycolysis
under normoxia and hypoxia in MDA-MB-231 cells by
Table 1 Fraction and percentage of mice in each treatment group with re-occurring primary tumors, and with
intestinal, mesentery, lymph node, and pulmonary metastatic involvement
untreated bicarbonate DCA DB
Re-occurring primary tumors 12/15 (80%) 6/13 (46.2%) 11/15 (73.3%) 7/15 (46.7%)
Intestinal 5/14 (35.7%) 0/11 (0%) 3/14 (21.4%) 2/15 (13.3%)
Mesentery 2/14 (14.3%) 0/11 (0%) 2/14 (14.3%) 3/15 (20%)
Lymph node 9/14 (64%) 3/11 (27%) 5/14 (35.7%) 7/15 (47%)
Lung 11/14 (78.6%) 1/13 (7.7%) 6/13 (46.2%) 10/15 (66.7%)
Figure 3 Primary tumor re-occurrence after survival surgeries. Survival surgeries occurred between day 28 and 50. Average resection day
occurred on day 37 ± 8. Primary tumor sizes in all treatment groups averaged 490 ± 12 mm
3. Primary tumors started to re-grow around day 50.
Primary tumor re-occurrence is plotted over the survival time course as Kaplan-Meier curve. A plot point represents the day when a primary
tumor was first measured after surgery. In mice where no primary tumor was observed in post-study necropsy experiments, a value of zero was
recorded for day 120. A) Plots for all experimental cohorts (p = 0.29). B) Curves comparing groups that were not administered bicarbonate
(untreated and DCA) and groups treated with bicarbonate (bicarbonate and DB) (p = 0.046).
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from 2.5 to 80 mM inhibited glycolysis between 19%
and 29% in MDA-MB-231 cells cultured under nor-
moxia. Reduction in lactate production was significant
in all doses (p < 0.05) with the exception of the 40
mM concentration (p = 0.059) (Figure 7A). Alterna-
tively, under hypoxic conditions, DCA at the same
dose range had no measurable effect on lactate pro-
duction (Figure 7B).
Discussion
The premise for these experiments was based on mathe-
matical models that suggest the buffering capacity of
bicarbonate against tumor acidity could be safely
enhanced by addition of DCA (Martin N, Robey I, Gaff-
ney E, Gillies R, Gatenby R, Maini P: Predicting the
Safety and Efficacy of Buffer Therapy to Raise Tumor
pHe: An Integrative Modeling Study, submitted). The
model indicated that inhibition of tumor proton produc-
tion by a relatively small amount could cause substantial
reductions in tumor acidity, without any adverse effects
on blood pH. A reagent like DCA fits this criterion
because it can reduce extracellular tumor acidity by
inhibiting lactic acid production. Moreover, DCA has
been shown to selectively target tumor cells [17,18]. The
design of this study was to treat our mouse model for
breast cancer as similar to a patient study as possible by
carrying out a survival experiment with surgical tumor
resections.
We confirmed from both urine and serum pH mea-
surements that addition ofc h r o n i cD C Aa tt h ed o s e s
administered did not cause significant changes in either
urine or serum pH. The urine and serum pH results
from DB treated mice were statistically comparable to
the measurements in the bicarbonate treated group. We
conclude from these findings that DCA does not induce
any systemic perturbations that could lead to systemic
alkalosis.
Our studies show that none of the treatments reduced
primary tumor growth. Our bicarbonate treatment
group results were consistent with earlier studies [16].
Figure 4 Effect of bicarbonate, DCA, and DB on and survival. MDA-MB-231 cells were stably transfected to express neomycin-resistant
pcDNA3/EGFP (16). MDA-MB-231/eGFP cells (5 × 10
6) were injected into inguinal mammary fat pads of animals that were randomized into
bicarbonate, DCA, DB, and control groups (n = 16 per group) 6 days post inoculation. Tumors were allowed to grow for 5 to 6 wk (to a volume
of approximately 500 mm
3), at which time they were surgically removed. After survival surgeries, the disease model was allowed to progress
until tumor burdens or morbidity criteria warranted the mice to be euthanized. The survival experiment proceeded to day 120. At time of
sacrifice, mice were necropsied by examination with a fluorescence dissecting scope. Data from this experiment are plotted as Kaplan-Meier
survival curves (A) bicarbonate (p = 0.03), (B) DCA (p = 0.2), and (C) DB (p = 0.01). Treated mice are represented as solid lines compared to the
untreated group represented as a dashed line. The difference in the survival curve for the treated versus untreated animals was evaluated by
log-rank test.
Table 2 Metastases observed in mice that survived
greater than 120 days
metastases untreated bicarbonate DCA DB
positive 1 4 3 8
negative 2 3 3 2
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bits tumor growth rates in vivo [17]. We expected to see
t h i sr e s u l ta sw e l l ,b u tf o u n dt h a tD C Aa n dD Bt r e a t e d
mice had similar primary tumor growth rates to
untreated and bicarbonate treated mice. This difference
may be explained by the variable effect DCA can have
in different tumor cell lines [20,21]. With respect to the
metastases results, our findings were similar to a study
that administered 5 mM DCA orally to rats injected
with a metastatic breast tumor line through the tail
vein. There was no measurable effect of the 5 mM dose
[21].
It is unknown why DCA treatment did not provide
therapeutic benefit against tumors in mice, but the
in vitro studies may help to explain our findings. The
viability studies under normoxic conditions demonstrate
that tumor cells have a biphasic response to titrating
DCA concentrations. This occurrence is known as
hormesis, where low doses can be agonistic and higher
doses are toxic to cancer cells [22]. The normoxic
Table 3 Summary of pulmonary lesions in treatment groups
Untreated Bicarbonate DCA DB
Lungs analyzed per group 10 1 6 9
Total number of lesions 77 32 71 122
Metastases area sum (lesion pixels) 56090 39289 47428 26897
Metastases area mean (lesion pixels ± SEM) 728 ± 105 1228 ± 220* 668 ± 77 220 ± 18**
Metastases area median (lesion pixels) 447 720 419 160
Metastases lesion areas were determined by measurement of the two-dimensional pixel area. Two diseased lungs, one from the untreated group and one from
the DB treated group, could not be reliably measured to include in the analysis. A single asterisk (*) designates lesion areas that were significantly different from
pulmonary lesions in untreated mice (p < 0.05). A double asterisk (**) designates lesion areas that were significantly different from pulmonary lesions in untreated
mice (p < 0.001).
Figure 5 Representative pulmonary lesions from the four study cohorts. Green fluorescent lung tumor metastases from necropsies were
detected by the Illumatool Bright Light System (LT-9500) using a 470 nm/40 nm excitation filter (Lightools Research). Whole lung images were
captured in the frame of view at the same focal plane in the presence of 480-nm excitation and > 490-nm filtered emission.
Robey and Martin BMC Cancer 2011, 11:235
http://www.biomedcentral.com/1471-2407/11/235
Page 7 of 10in vitro viability results suggest DCA concentrations at
20 mM or lower could have a stimulatory effect in vivo,
though this was not measured. Only at concentrations
exceeding 20 mM did DCA reduce viability under nor-
moxia. Under hypoxia, DCA concentrations at 20 mM
or lower had no effect on viability. There was a mar-
ginal, but significant reduction in viability at DCA con-
centrations greater than 20 mM under hypoxia. An 80
mM concentration was required to reduce viability 50%.
In the lactate production studies, DCA doses at 20 mM
or lower significantly reduced MDA-MB-231 cell glycoly-
tic metabolism under normoxia by approximately 19%.
Doses higher than 20 mM inhibited lactate production by
29% under normoxia. No concentration of DCA tested
reduced cellular lactate production under hypoxia. The
in vitro studies suggest; 1) that DCA concentrations
greater than 20 mM may have a non-specific effect on
MDA-MB231 cells and 2) hypoxia may be a factor con-
tributing to the in vivo findings.
MDA-MB-231 mammary xenografts are known to
develop regions of hypoxia due to the development of
necrotic lesions. Also, unpublished experiments (Robert
Gillies laboratory at the University of Arizona) imaging
MDA-MB-231 tumors in mice with bioluminescent
reporters linked to promoter regions for hypoxia
response elements such as VEGF or CAIX demonstrate
that tumors develop regions of hypoxia (exhibit biolumi-
nescence) as soon as tumors become palpable (between
100-200 mm
3). Other studies have shown the link
between DCA function and hypoxia. DCA inhibits pyru-
vate dehydrogenase kinase-1 (PDK1) which inhibits cel-
lular metabolism and causes oxygen consumption
resulting in increased hypoxia [23,24].
Although the metastatic load observed in bicarbonate
treated mice appeared markedly lower than reported in
DB treated mice (especially mesentery and intestinal), the
data is insufficient to conclude that bicarbonate mono-
therapy was more effective at reducing the spread of
metastases. The major impact on survival in our cancer
model is lung metastases. As seen in the untreated group,
most (79%) of the animals showed evidence of metastatic
lung lesions. Only one of the bicarbonate treated animals
in the analysis was found to have lung metastases, but
there were two (of the four) spontaneous deaths that
Figure 6 MDA-MB-231 breast tumor cells were cultured for 24 hours (n ≥ 3) with titrating doses of DCA starting from 80 mM and
diluted 2-fold to the lowest concentration of 2.5 mM. Percent viability for all groups of replicates was normalized by dividing absorbance
(590 nm) values by the absorbance values obtained from sham treated (growth media) control cells. Cytotoxicity by DCA in a crystal violet assay
was carried out under A) normoxia (O2 = 20%) and B) hypoxia (O2 = 1%). Asterisks (*) designate viable DCA treated cells percentage that were
significantly different from 100% viable sham treated cells. Error bars are expressed as SEM.
Figure 7 MDA-MB-231 breast tumor cells were cultured for 24 hours with titrating doses of DCA starting from 80 mM and diluted 2-
fold to the lowest concentration of 2.5 mM (n ≥ 3). Supernatant lactate was measured as a ratio of the total cellular protein. Lactate
production was measured under A) normoxia (O2 = 20%) and B) hypoxia (O2 = 1%). Asterisks (*) designate lactate production in DCA treated
cells percentage that were significantly different from untreated control cells. Error bars are expressed as SEM.
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where we were unable to analyze the lungs. Nonetheless,
a two-tailed Fischer’s exact analysis shows that including
the bicarbonate treated group spontaneous deaths as
lung metastases positive (23%) and the untreated as nega-
tive for lung metastases, frequency of lung metastases
would still be significantly lower in the bicarbonate trea-
ted mouse group (p = 0.02). It was surprising that the
percentage of DB treated mice with lung metastases was
60%, and not significantly different from the occurrence
of lung metastases in the untreated mouse group, indicat-
ing the bicarbonate monotherapy as a more favorable
treatment modality at least in this tumor model. The
findings suggest a potential risk in the DB treatment that
would need to be investigated further in other models for
cancer.
Analysis of the pulmonary lesions revealed that DB
treatment resulted in significantly smaller mean tumor
metastases compared to all other groups. The mean
lesion diameter in DB treated mouse lungs was no larger
than 30% of the lesion diameters in the other treatment
groups. In a previous study it was reported that smaller
tumor metastases in lungs was correlated significantly
with bicarbonate treatment alone, but this was a 30 day
experiment using b-galactosidase expressing MDA-MB-
231 cells and the mean tumor diameters were about 87%
of the lesion diameters measured in the untreated group
[16]. The comparison of tumor lesion sizes between the
metastasized lungs in all the study groups appears to sug-
gest that DB treatment inhibits the growth of these
metastases (Table 3). However, given the prevalence of
non-metastatic lungs in the bicarbonate treated group, it
c o u l db ea r g u e dt h a tD C Ah a sm o r eo fas t i m u l a t o r y
effect, especially if O2 concentrations are more normoxic,
and may even compete with bicarbonate therapy. This
conclusion is supported by the in vitro findings which
show that lower concentrations of DCA increase cell via-
bility under normoxia.
Improved survival was a significant outcome in all
groups treated with bicarbonate. There seemed to be lit-
tle measurable therapeutic effect in DCA treated mice,
suggesting bicarbonate was a driving component in the
survival study. The results are consistent with earlier
findings [16], but the mechanisms are not well under-
stood. More than half the primary tumors in bicarbonate
and DB treated mice did not return after surgical resec-
tions. We attribute the lower frequency of primary tumor
re-occurrence to the improved survival rates in these
groups. The difference between bicarbonate treated
groups (bicarbonate and DB) and non-bicarbonate trea-
ted groups (untreated and DCA) in tumor re-occurrence
after surgeries is statistically significant (p < 0.05). It may
be possible that the effect of systemic bicarbonate could
potentiate the wound healing process after surgical
disruption of the tumor region. The role of bicarbonate
ions (HCO3
-) in wound repair was first reported in a
study investigating gastric mucosal repair in cats systemi-
cally administered sodium bicarbonate. It was concluded
that systemic excess of HCO3
- facilitated superficial
mucosal repair [25]. The molecular mechanisms driving
this effect are unknown, but other reports have shown
that blocking the Na
+-HCO3
- co-transport (NBC) with
isothiocyanate (ITC) inhibits epithelial restitution, the
process of epithelial migration involved in wound heal-
ing. Additionally, cell migration during restitution is
dependent on glycolysis for energy [26]. This is notable
because NBC functionally cooperates with monocarboxy-
late lactate transporter (MCT-1), a glycolysis-associated
enzyme. Extracellular HCO3
- increases NBC activity,
which in turn enhances MCT activity leading to an
increase in intracellular pH [27], a physiological condi-
tion conducive to glucose metabolism [28]. It is thought
that the upregulated glycolytic activity of tumor cells
offers a competitive advantage over surrounding host
cells [14]. The epithelial wound healing processes after
tumor resection in conjunction with an increase in extra-
cellular bicarbonate may improve the competitive state of
some host cells in the tumor microenvironment, and
result in prevention of primary tumor re-growth.
Although further evidence for these processes is required,
it suggests that an optimal time to administer systemic
bicarbonate would be after a tumor surgery.
Conclusions
This study confirms earlier reports about the role of sys-
temic bicarbonate in the inhibition of metastatic spread
from primary tumors, but highlights the limitations of
this approach. While DCA has been shown both safe and
effective against tumor cells in other studies, the findings
reported here concur with the most recent investigations
warning of potential pitfalls with DCA use [23,24]. First,
it is not universally effective against all cancer cells. Sec-
ondly, tumor hypoxia serves as a confounding micro-
environmental factor against DCA efficacy. The unpre-
dictable effect of DCA against tumors therefore signals
caution against using this agent as a therapeutic approach
until new studies can determine the molecular role of
DCA in different tumor microenvironments.
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